

Azerbaijan

Population 2017

9.8 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.86 (0.81–0.9)	8.7 (8.2–9.2)
Mortality (HIV+TB only)	0.023 (0.017–0.031)	0.24 (0.17–0.31)
Incidence (includes HIV+TB)	6.5 (5–8.3)	67 (51–84)
Incidence (HIV+TB only)	0.11 (0.071–0.16)	1.1 (0.72–1.6)
Incidence (MDR/RR-TB)**	1.5 (1.1–1.9)	15 (11–19)

Estimated TB incidence by age and sex (thousands)*, 2017

	0-14 years	> 14 years	Total
Females	0.36 (0.23–0.5)	2 (1.2–2.7)	2.3 (1.5–3.1)
Males	0.4 (0.25–0.55)	3.8 (2.4–5.2)	4.2 (2.8–5.6)
Total	0.77 (0.55–0.98)	5.8 (4.2–7.4)	6.5 (5–8.3)

TB case notifications, 2017

Total cases notified	7 129
Total new and relapse	5 231
- % tested with rapid diagnostics at time of diagnosis	55%
- % with known HIV status	83%
- % pulmonary	80%
- % bacteriologically confirmed among pulmonary	74%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.14 (0.1–0.17)

TB/HIV care in new and relapse TB patients, 2017

	Number	(%)
Patients with known HIV-status who are HIV-positive	95	2%
- on antiretroviral therapy	79	83%

Drug-resistant TB care, 2017	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 300 (1 200–1 300)
Estimated % of TB cases with MDR/RR-TB	12% (11–14)	28% (27–30)	
% notified tested for rifampicin resistance	54%	86%	4 908
MDR/RR-TB cases tested for resistance to second-line drugs			614
Laboratory-confirmed cases		MDR/RR-TB: 1 007, XDR-TB: 118	
Patients started on treatment ****		MDR/RR-TB: 858, XDR-TB: 182	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2016	84%	1 464
Previously treated cases registered in 2016	74%	2 220
HIV-positive TB cases registered in 2016		
MDR/RR-TB cases started on second-line treatment in 2015	59%	800
XDR-TB cases started on second-line treatment in 2015		

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment	52%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	98% (72–100)

TB financing, 2018

National TB budget (US\$ millions)

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically